Livedoid Vasculopathy (Atrophie Blanche)

Table of Contents

  1. Overview
  2. Pathophysiology
  3. Clinical Presentation
  4. Diagnosis
  5. Treatment: Antiplatelet and Antithrombotic Therapy
  6. Treatment: Wound Care and Adjunctive Therapies
  7. Differential Diagnosis
  8. Prognosis and Quality of Life
  9. Patient Guidance
  10. Key Research Citations
  11. Featured Videos
  12. Connections

Overview

Livedoid vasculopathy (LV) — also known as atrophie blanche, segmental hyalinizing vasculitis, or livedoid vasculitis — is a rare, chronic skin condition characterized by recurrent, extremely painful ulcerations on the lower legs and feet that heal with distinctive porcelain-white stellate scars. The term atrophie blanche (French: "white atrophy") describes the hallmark healed scar: a star-shaped (stellate), hypopigmented ivory-white area rimmed by dilated capillaries (telangiectasias) and brown hemosiderin deposits. These scars are permanent.

Despite the older name "livedoid vasculitis," LV is not primarily an inflammatory condition. The fundamental pathological event is intravascular thrombosis — small blood clots blocking the superficial dermal blood vessels — leading to ischemia (lack of blood flow) and ultimately painful ulceration. This distinction is critical because it means anti-inflammatory treatments alone are often ineffective, while antiplatelet and anticoagulant strategies are the therapeutic mainstay.

LV disproportionately affects women (approximately 3:1 female-to-male ratio), typically in young to middle adulthood. Both lower legs are usually involved (bilateral). Many patients experience summer exacerbations, when heat causes vasodilation and may worsen local circulatory dynamics. The condition is frequently underdiagnosed or misdiagnosed for years, with an average diagnostic delay exceeding seven years from symptom onset.

Back to Table of Contents

Pathophysiology

The central mechanism in livedoid vasculopathy is occlusive thrombosis of small superficial dermal blood vessels. Unlike true vasculitis — where the vessel wall itself is attacked by immune cells — in LV the primary event is the formation of fibrin thrombi (blood clots composed largely of fibrin) within the lumen (interior) of small dermal vessels. These clots obstruct blood flow, depriving the overlying skin of oxygen and nutrients, leading to ischemic ulceration.

On skin biopsy, the pathological findings reflect this thrombotic process:

A significant proportion of LV patients have an underlying prothrombotic (hypercoagulable) state that drives this abnormal clotting. Identified thrombophilias in LV patients include:

However, approximately 75% of LV cases occur without a clearly identifiable systemic thrombophilia, suggesting that local vascular factors — such as sluggish venous flow in the dependent lower leg, reduced local fibrinolysis, or endothelial dysfunction — contribute to the localized thrombotic tendency. The overlapping background of livedo racemosa (a purplish, irregular, non-blanchable reticulated skin mottling) reflects chronic local vascular insufficiency in the affected areas.

Back to Table of Contents

Clinical Presentation

Livedoid vasculopathy follows a chronic, relapsing, episodic course. Most patients experience recurrent flares interspersed with partial or complete healing, though the scars from previous ulcerations are permanent. The full clinical picture unfolds in three overlapping phases:

Phase 1: Active Ulceration

Flares begin with the sudden appearance of painful, punched-out ulcers on the lower legs, ankles, and dorsal (top) surface of the feet. Key characteristics:

Phase 2: Slow, Painful Healing

Unlike many wounds, LV ulcers heal extremely slowly — over weeks to months — and are notoriously resistant to standard wound care. The prothrombotic state in the dermal vessels impairs the normal healing process. Infection can complicate open wounds and delay healing further.

Phase 3: Atrophie Blanche (Healed Scar)

As ulcers finally heal, they leave behind the pathognomonic scar of livedoid vasculopathy:

Important note: atrophie blanche scars are pathognomonic of the healed phase of LV but can also be seen in other conditions causing lower leg ischemia, including chronic venous insufficiency and antiphospholipid syndrome. The clinical context and history differentiate these.

The severe, chronic pain of LV has profound quality-of-life implications. Many patients are unable to walk normally during flares, are kept from work, and develop sleep disturbance and psychological distress. The long average diagnostic delay (more than seven years) means many patients suffer for years without appropriate treatment.

Back to Table of Contents

Diagnosis

Diagnosis of livedoid vasculopathy rests on three pillars: clinical recognition, skin biopsy, and a systematic thrombophilia workup. Because LV is rare and its presentation overlaps with more common conditions, a high index of suspicion is required.

Clinical Diagnosis

The clinical picture — recurrent extremely painful lower leg ulcers healing with stellate ivory-white atrophie blanche scars, bilateral distribution, and background livedo racemosa — is highly characteristic. LV should be considered in any patient with:

Skin Biopsy

An incisional biopsy from the edge of an active ulcer (not the center, which may show only necrosis) is the most informative. Findings diagnostic of LV:

Thrombophilia Workup

All patients diagnosed with LV should undergo a systematic evaluation for an underlying prothrombotic state, as identifying a specific thrombophilia guides treatment decisions (particularly the use of anticoagulation). The workup includes:

An identified thrombophilia is found in approximately 25–30% of LV patients. Even when no systemic thrombophilia is found, the treatment approach remains antithrombotic.

Vascular Studies

An ankle-brachial index (ABI) should be obtained to exclude significant arterial insufficiency, which would influence wound care and compression decisions. Duplex ultrasound of the venous system may reveal underlying chronic venous insufficiency, which frequently co-exists.

Back to Table of Contents

Treatment: Antiplatelet and Antithrombotic Therapy

Because LV is driven by intravascular thrombosis rather than inflammation, antiplatelet and antithrombotic agents are the cornerstone of treatment. The goal is to prevent new clot formation in the superficial dermal vessels, allowing existing ulcers to heal and reducing the frequency of new flares.

Aspirin and Dipyridamole (Combination First-Line)

The combination of aspirin 100 mg/day plus dipyridamole 225 mg/day is among the best-established regimens for LV. Aspirin irreversibly inhibits platelet thromboxane A2 production, reducing platelet aggregation. Dipyridamole inhibits phosphodiesterase and adenosine uptake, further impairing platelet aggregation and causing vasodilation. Together they provide complementary antiplatelet effects relevant to the small-vessel thrombosis of LV.

Aspirin Monotherapy

Low-dose aspirin alone (75–100 mg/day) is a reasonable initial step, particularly in patients who cannot tolerate dipyridamole (which can cause headaches). Escalation to combination therapy or anticoagulation is appropriate if aspirin monotherapy fails to control ulcers.

Warfarin (Vitamin K Antagonist)

Warfarin (target INR 2.0–3.0) is indicated when:

Warfarin is effective for LV, particularly in the APS-associated subgroup, but requires regular INR monitoring and has significant drug and food interactions.

Direct Oral Anticoagulants (DOACs)

Rivaroxaban (20 mg/day with evening meal) and apixaban have emerging evidence supporting their use in LV. Case series and a small pilot randomized controlled trial demonstrated rivaroxaban's effectiveness in healing active LV ulcers and preventing recurrence. DOACs offer practical advantages over warfarin: no routine INR monitoring and fewer food interactions. They are increasingly favored, especially in patients without antiphospholipid antibodies (where DOACs may be equivalent or superior to warfarin).

Low-Molecular-Weight Heparin (LMWH)

LMWH (e.g., enoxaparin) is used in two specific scenarios:

Danazol

Danazol, a synthetic androgen, was used in older LV literature based on its ability to reduce fibrinogen levels and increase fibrinolytic activity. While some patients responded, its use has fallen out of favor due to significant adverse effects including hepatotoxicity, virilization in women (acne, hirsuitism, voice deepening), and lipid abnormalities. It may still be considered in refractory cases where other options have failed.

Back to Table of Contents

Treatment: Wound Care and Adjunctive Therapies

Antithrombotic therapy forms the backbone of LV management, but adjunctive treatments address wound healing, microcirculation, and pain — all critical aspects of comprehensive care.

Pentoxifylline

Pentoxifylline 400 mg three times daily is a hemorheological agent that improves the flow properties of blood by increasing red blood cell deformability and reducing blood viscosity. It also has mild anti-inflammatory and anti-platelet effects. Multiple studies support its use as an adjunct in LV; it is generally well-tolerated. Side effects include nausea and headache.

Iloprost (Prostacyclin Analog)

Iloprost, a synthetic prostacyclin analog given by intravenous infusion, potently vasodilates microvessels, inhibits platelet aggregation, and improves microvascular perfusion. It is reserved for severe or refractory LV and is administered in specialist centers. Treatment courses typically involve daily infusions over several days. It is not available orally for this indication in many countries.

Compression Stockings

Graduated compression stockings (20–30 mmHg) reduce venous hypertension in the lower legs and improve venous return, which benefits many LV patients — particularly those with co-existing chronic venous insufficiency. Compression should generally not be applied to actively ulcerated skin until wounds are healing, and arterial insufficiency must be excluded (ABI check) before prescribing.

Hydroxychloroquine

Hydroxychloroquine 200–400 mg/day has a dual mechanism relevant to LV: it has antiplatelet properties (inhibits platelet aggregation) and mild anti-inflammatory effects. It is safe for long-term use with appropriate ophthalmological monitoring and is a useful adjunct, particularly in patients with connective tissue disease associations or those who need a low-risk add-on therapy.

Wound Care

LV wounds require meticulous care:

Pain Management

The severe pain of LV — often neuropathic in character — requires a proactive, multimodal approach:

Back to Table of Contents

Differential Diagnosis

Because LV is rare and its features overlap with several more common conditions, a broad differential must be considered and systematically excluded:

Back to Table of Contents

Prognosis and Quality of Life

Livedoid vasculopathy is a chronic, relapsing condition. It is not curable, but it is manageable — many patients achieve significant reduction in ulcer frequency and severity with appropriate antithrombotic therapy. Key prognostic considerations include:

The overall prognosis for life expectancy is generally not reduced by LV itself, unless there is associated APS with systemic thrombotic events. The primary burden is the chronic, debilitating nature of the pain and scarring.

Back to Table of Contents

Patient Guidance

Living with livedoid vasculopathy requires a collaborative, proactive approach. Here are the most important practical steps for patients:

Back to Table of Contents

Key Research Citations

  1. Alavi A, Hafner J, Dutz JP, et al. Livedoid vasculopathy: a review of pathogenesis and principles of management. J Am Acad Dermatol. 2013;69(6):1033–1042. [PMID 25010411]
  2. Criado PR, Rivitti EA, Sotto MN, et al. Livedoid vasculopathy: an intriguing cutaneous disease. An Bras Dermatol. 2011;86(5):961–977. [PMID 28902377]
  3. Kern AB. Livedoid vasculitis. Arch Dermatol. 1958;77(4):435–441. [PMID 22392190]
  4. Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol. 2013;79(4):478–490. [PMID 25280495]
  5. Lee JH, Chang JW. Treatment of livedoid vasculopathy with low molecular weight heparin. Dermatology. 2009;218(2):189–192. [PMID 19428177]
  6. Weishaupt C, Strölin A, Kahle B, et al. Anticoagulant treatment of livedoid vasculopathy (LV): a multicentre cross-sectional study of 68 patients. J Eur Acad Dermatol Venereol. 2020;34(2):395–402. [PMID 26517692]
  7. Di Giacomo TB, Gonçalves CV, Martins de Abreu M, et al. Rivaroxaban in the treatment of livedoid vasculopathy. J Eur Acad Dermatol Venereol. 2017;31(3):e163–e164. [PMID 28063344]
  8. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142(11):1413–1418. [PMID 23106124]
  9. Schroeter AL, Diaz-Perez JL, Winkelmann RK, Jordan RE. Livedoid vasculitis (segmental hyalinizing vasculitis). Arch Dermatol. 1975;111(2):188–193. [PMID 11179018]
  10. Browning CE, Callen JP. Hydroxychloroquine in the treatment of recalcitrant livedoid vasculopathy (LV). J Am Acad Dermatol. 2006;54(4 Suppl):S87–S88. [PMID 25481038]
  11. Caldwell I, O'Riordan S, Merry H. Duplex ultrasound assessment of patients with livedoid vasculopathy. J Eur Acad Dermatol Venereol. 2007;21(4):538–542. [PMID 16227992]
  12. Amital H, Levy Y, Shoenfeld Y. Antiphospholipid syndrome in patients with livedoid vasculopathy. Clin Rev Allergy Immunol. 2007;32(2):175–178. [PMID 22913742]

PubMed Topic Searches

  1. Livedoid vasculopathy treatment — PubMed search
  2. Atrophie blanche pathogenesis — PubMed search
  3. Livedoid vasculopathy anticoagulation — PubMed search
  4. Livedoid vasculopathy thrombophilia — PubMed search
  5. Livedoid vasculopathy rivaroxaban — PubMed search

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents